Stryker Sticks to Growth Goals Despite Cyberattack and Slower Orthopedic Market

Stryker logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Stryker reaffirmed its growth and profitability targets despite a cyberattack and a slower orthopedic market, including 150 basis points of adjusted operating margin expansion over three years and free cash flow of about 70%–80%. Efficiency measures could help sustain margins if sales growth slows, particularly in 2026.
  • Most cyberattack effects are expected to persist through 2026, but Stryker says it expects to recover missed business that year. Supply at its Inari business has stabilized, with supply expected to meet demand entering 2027.
  • The U.S. large-joint hip and knee market is growing about 2.5%, as economic pressures lead some patients to delay procedures; Stryker expects a gradual recovery while continuing to gain knee share. Hospital demand remains strong, with long order lead times for beds, stretchers and operating-room infrastructure.
  • Interested in Stryker? Here are five stocks we like better.

Stryker NYSE: SYK expects to maintain its long-term growth and margin goals despite a cyberattack, supply disruptions and a softer U.S. orthopedic market, executives said at the London Healthcare Conference.

President and Chief Operating Officer Spencer Stiles, who is set to become CEO in January, said the medical technology company continues to target growth at the high end of its markets and 150 basis points of adjusted operating margin expansion over a three-year period. He also reiterated an annual free cash flow target of about 70% to 80%.

Chief Financial Officer Preston Wells said efficiency improvements could support the margin goal even if sales growth is somewhat slower, particularly in 2026. The company is examining product transfers into its own facilities, greater use of lower-cost plants in Warsaw and Mexico, and ways to streamline support functions.

Cyber Disruption and 2027 Comparisons

Stiles said most of the effects from the cyberattack should remain in 2026. Stryker temporarily shut down operations as it worked to secure and restart systems, with the most significant lingering supply disruption affecting its Inari business.

Inari supply has become more stable in the fourth quarter, Stiles said, and the company expects supply to meet demand as it enters 2027. He said the business had recorded some of its strongest months of the year in recent months.

Wells said Stryker expects to make up in 2026 any business missed because of the cyberattack, rather than carrying cyber-related pushouts into 2027. He cautioned, however, that quarterly comparisons next year will be uneven. First-quarter growth should be strong against a weak year-earlier period, while later quarters may face some residual effects from the disruption.

Orthopedic Market and Capital Demand

Stiles said Stryker estimates the U.S. large-joint hip and knee market is growing at about 2.5%. He attributed the market’s softness primarily to economic pressures that can cause patients to delay procedures, with some insurance denials also contributing.

He expects a gradual recovery rather than an immediate rebound. Stryker continues to gain share in knees, growing at approximately 1.3 times the U.S. market rate in 2026, he said.

The company plans to launch a hip impactor in the second half of 2027 to address a gap in its portfolio. Stiles also pointed to the rollout of its handheld Mako RPS robotic system and newer knee implants as products that could support future share gains.

Hospital capital demand remains strong, according to Stiles. Orders for beds and stretchers have lead times of roughly six to nine months, while orders in the company’s operating-room infrastructure business can extend from one year to 18 months. He said Stryker had not seen order cancellations following the cyberattack.

Wells said the company is monitoring potential effects of the U.S. 340B program on hospital finances, though he said Stryker is still assessing what those effects could mean.

Robotics Partnership and Deal Priorities

Stiles said acquisitions remain Stryker’s top priority for deploying cash. The company has made a strategic investment in soft-tissue robotics company CMR and will build a U.S. sales channel for it, but has not purchased the business.

Sales made through that channel will be recorded by CMR, with Stryker receiving a fee, Stiles said. Stryker also has an option to buy CMR in the future. The arrangement gives Stryker time to assess the business’s manufacturing, costs and commercial strategy, he said.

Stiles identified healthcare information technology, men’s and women’s health, soft-tissue robotics and neurotechnology as areas of interest for future deals. He said the company’s primary focus would remain on tuck-in acquisitions, though those deals may be larger as Stryker grows.

The company also expects to continue modest share repurchases, primarily to offset dilution, and to grow its dividend modestly over time, Stiles said.

About Stryker (NYSE:SYK)

Stryker is a medical technology company that develops and sells products and services for healthcare providers. Its offerings include orthopedic implants and surgical equipment, neurotechnology and spine products, and medical and surgical equipment used in hospitals and other care settings. The company's products also include patient-handling and emergency medical equipment, as well as instruments and technologies that support surgical procedures. Stryker serves healthcare customers in the United States and internationally.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Stryker Right Now?

Before you consider Stryker, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.

While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines